ÂÜÀòÂÒÂ×

Dr. Fuller is a Professor Emeritus, Department of Cell Biology at the University of Alabama Medical School with expertise in molecular biology, progenitor cell biology, and vascular biology. He was the first scientist to develop antibodies to tubulin as a tool to understand how the cellular cytoskeleton is involved in cancer. He was also one of the first scientists to discover IL-6 and its involvement in stimulating hepatocytes as part of the acute phase response. Through over 30 years of Medical School teaching, he has developed an extensive background in anatomy, cellular structures, and physiology of living organisms. Dr. Fuller has been a scientific consultant with Chrysalis BioTechnology, OrthoLogic, and Merck and currently directs a team of scientists working to better understand the molecular mechanisms by which TP508 targets progenitor cells to protect and regenerate tissues. These studies are crucial to the current focus on mitigating effects of radiation with TP508 and understanding the pulmonary and vascular effects of COVID ARDS and how TP508 may mitigate these effects. Additional collaborative studies include potential future clinical use of TP508 in treating Traumatic Brain Injury and neurological degenerative diseases.